The collaboration will bring Cortechs.ai's quantitative MRI analysis into Viz.ai's care coordination platform, beginning with ...

TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with ...

According to the latest market analysis by Future Market Insights, the global B-Cell Depletion Therapy Market is projected to ...

As the erratic southwest monsoon continues in Karnataka for the second consecutive month, Bengaluru continues to reel under a ...

If the data LLMS learned from reflects a world where women are paid less, it’s no surprise that their advice does too ...

Arras Minerals Corp. ("Arras" or "Arras Minerals" or "the Company") wishes to announce that following the closing of the upsized $25 million Bought Deal financing this week, the company is expanding ...

Scientists find immune markers that may catch Lyme disease earlier and explain why some patients' symptoms linger.

I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.

Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly ...

Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of ...